Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coronavirus test maker Co-Diagnostics late Thursday reported earnings and revenue that missed Wall Street expectations, and the company's stock fell more than 10% in after-hours trading.
The post Coronavirus Test Maker Earnings, Sales Fall Short Of Views; CODX Stock Falls appeared first on Investor's Business Daily.

Coronavirus Test Maker Earnings, Sales Fall Short Of Views; CODX Stock Falls

SALT LAKE CITY, Aug. 13, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Announces Q2 2020 Results on Form 10-Q

Los Angeles, California--(Newsfile Corp. - August 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc.

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #CODX--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Co-Diagnostics, Inc.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc.

Los Angeles, California--(Newsfile Corp. - August 12, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc.

MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.

Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?

SALT LAKE CITY, Aug. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Announces Q2 2020 Earnings Release Date and Earnings Webcast

LOS ANGELES, Aug. 10, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Co-Diagnostics, Inc.

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc. (CODX)

The COVID-19 pandemic has lit a fire under this diagnostics company's stock.

Why Co-Diagnostics Stock Surged 24% in July

NEW YORK, Aug. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Investors of Important August 17 Deadline in Securities Class Action - CODX

In the latest trading session, CoDiagnostics, Inc. (CODX) closed at $25.73, marking a -1.61% move from the previous day.

CoDiagnostics, Inc. (CODX) Stock Sinks As Market Gains: What You Should Know

SALT LAKE CITY, Aug. 7, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Logix Smart™ COVID-19 Test Authorized for Use in Australia

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

CoDiagnostics, Inc. (CODX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

New York, New York--(Newsfile Corp. - August 4, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc.

Co-Diagnostics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

The FDA has approved emergency use of its at-home COVID-19 test.

Why Co-Diagnostics Skyrocketed 28.3% Today

Co-Diagnostics Inc (NASDAQ: CODX) shares were headed higher Monday after the company said the FDA has authorized the use of its technology in a third-party, self-administered COVID-19 test.

Why Shares Of Co-Diagnostics Are Soaring

SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Technology to be Used in FDA-Authorized Self-Collected COVID-19 Saliva Test

With a desperate need for more test test kits for the novel coronavirus, shares of CODX stock could continue to trend higher.
The post The Top Reasons to Consider Co-Diagnostics Stock appeared first on InvestorPlace.

The Top Reasons to Consider Co-Diagnostics Stock

In the latest trading session, CoDiagnostics, Inc. (CODX) closed at $22.12, marking a +1.37% move from the previous day.

CoDiagnostics, Inc. (CODX) Outpaces Stock Market Gains: What You Should Know

New York, New York--(Newsfile Corp. - July 27, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Co-Diagnostics, Inc.

Co-Diagnostics Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Co-Diagnostics, Inc. To Contact The Firm

Novavax

Vaxart

These stocks have delivered gains of 2,300% and more. But could they go even higher?

3 Best-Performing Coronavirus Stocks of 2020 So Far: Are They Buys Now?

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between February 25, 2020 and May 15, 2020, inclusive (the “Class Period”), of the important August 17, 2020 lead plaintiff deadline in the securities class action.

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Investors of Important Deadline in Securities Class Action – CODX

NextEra Energy

Ollie's Bargain Outlet Hlds

QIAGEN

Boston Beer Company

Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility

Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks

GenMark Diagnostics

Immunomedics

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD

New York, New York--(Newsfile Corp. - July 15, 2020) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company") (NASDAQ: CODX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 and May 15, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...

CODX INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm

News for Co-Diagnostics Stock (CODX)